Abstract

What is this summary about? This is a summary of a clinical research study, which included men with osteoporosis to determine the efficacy (the ability of a medication to produce a desired effect or how "effective" the medication is) and safety of an injectable osteoporosis medication called abaloparatide (brand name Tymlos®). The study compared abaloparatide treatment to treatment with a placebo. The placebo injection was designed to look identical to abaloparatide but did not have an active ingredient.The US Federal Drug Administration (FDA) is a regulatory body that approved abaloparatide for the treatment of women who have been through menopause (postmenopausal women) with osteoporosis at high risk for breaking bones (also called "fractures"). The hormone estrogen, which is important for bone formation, is reduced after menopause, leading to an increased risk of osteoporosis. As a result of the ATOM study, abaloparatide is now also FDA approved to increase bone mineral density in men with osteoporosis at high risk of fractures. This summary includes a patient perspective on the study publication.